Phenotype-Based Drug Discovery & Development

Ash Biotech specialises in phenotype-based drug discovery and development. It is focused on enabling: determination of the efficacy and safety of potential new drugs in discovery and pre-clinical development; development of microscopic-scale disease models; and furthering understanding of the roles that targets play in disease (for example, through use of gene knockouts). The company has developed a portfolio of proprietary platform technologies, products and intellectual property, which are based around cutting-edge biology and innovative new approaches to medium- and high-throughput, high-content screening of microscopic model organisms.

The company was founded by European Biotech industry leaders who have pioneered: ultra high-throughput screening of small-molecule drugs; high-throughput and ultra-high-throughput screening of antibody drugs; and who played significant roles in the establishment of antibody drugs as the world's most important new class of drugs. The founders played key roles in growing biotech/pharma companies in Europe and the US to a combined exit value of over two and a half billion dollars. The company is privately held, and is located in Cambridge UK.

Ash Biotech has been developing its platform technology for the last four years, and will be revealing details of its technology, and its initial product offering, during 2011. If you would like us to let you know when we release more details, please send an email to news@ashbiotech.com and we'll keep you informed.